Kennedy Capital Management LLC Has $3.65 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Kennedy Capital Management LLC boosted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 281.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 111,098 shares of the biopharmaceutical company's stock after buying an additional 81,971 shares during the period. Kennedy Capital Management LLC owned approximately 0.19% of Agios Pharmaceuticals worth $3,651,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Venturi Wealth Management LLC purchased a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $53,000. KBC Group NV grew its holdings in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 611 shares during the last quarter. AlphaQuest LLC increased its stake in shares of Agios Pharmaceuticals by 106.2% during the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock worth $149,000 after purchasing an additional 2,338 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at $202,000.

Insider Activity

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Trading Up 1.9 %

AGIO traded up $0.52 during trading on Friday, reaching $27.66. 590,693 shares of the company were exchanged, compared to its average volume of 711,262. The firm has a 50 day moving average of $30.87 and a 200 day moving average of $38.78. The stock has a market cap of $1.58 billion, a P/E ratio of 2.44 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on AGIO shares. HC Wainwright began coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. StockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $56.57.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.